Chiara F. Corti

Milan, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 85 publications

Erratum: Decoding Clinical Trials in Metastatic Breast Cancer: Practical Insights for Optimal Therapy Sequencing.

Erratum: Decoding Clinical Trials in Metastatic Breast Cancer: Practical Insights for Optimal Therapy Sequencing.

Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

Published: November 21, 2025

Impact of pathologic response and individual prognosis after neoadjuvant treatment in patients with early HER2+ and triple-negative breast cancer.

Impact of pathologic response and individual prognosis after neoadjuvant treatment in patients with early HER2+ and triple-negative breast cancer.

Journal: Breast (Edinburgh, Scotland)

Published: October 03, 2025

Response to Letter to the Editor Re: Impact of the Prosigna assay on neoadjuvant treatment decision making in patients with early-stage HR-positive/HER2-negative breast cancer: a single-center prospective observational study.

Response to Letter to the Editor Re: Impact of the Prosigna assay on neoadjuvant treatment decision making in patients with early-stage HR-positive/HER2-negative breast cancer: a single-center prospective observational study.

Journal: ESMO open

Published: September 04, 2025

Artificial intelligence as treatment support in breast cancer: current perspectives.

Artificial intelligence as treatment support in breast cancer: current perspectives.

Journal: Breast (Edinburgh, Scotland)

Published: June 13, 2025

Decoding Clinical Trials in Metastatic Breast Cancer: Practical Insights for Optimal Therapy Sequencing.

Decoding Clinical Trials in Metastatic Breast Cancer: Practical Insights for Optimal Therapy Sequencing.

Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

Published: May 14, 2025

Impact of the Prosigna assay on neoadjuvant treatment decision-making in patients with early-stage HR-positive/HER2-negative breast cancer: a single-center prospective observational study.

Impact of the Prosigna assay on neoadjuvant treatment decision-making in patients with early-stage HR-positive/HER2-negative breast cancer: a single-center prospective observational study.

Journal: ESMO open

Published: April 10, 2025

ASO Author Reflections: Disparities in Refusal of Adjuvant Radiation for Breast-Conserving Therapy in the United States.

ASO Author Reflections: Disparities in Refusal of Adjuvant Radiation for Breast-Conserving Therapy in the United States.

Journal: Annals of surgical oncology

Published: April 08, 2025

Global disparities in artificial intelligence-based mammogram interpretation for breast cancer: A scientometric analysis of representation, trends, and equity.

Global disparities in artificial intelligence-based mammogram interpretation for breast cancer: A scientometric analysis of representation, trends, and equity.

Journal: European journal of cancer (Oxford, England : 1990)

Published: March 12, 2025

Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer.

Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer.

Journal: JAMA network open

Published: February 21, 2025

Clinicopathological features and genomics of ER-positive/HER2-negative breast cancer relapsing on adjuvant abemaciclib.

Clinicopathological features and genomics of ER-positive/HER2-negative breast cancer relapsing on adjuvant abemaciclib.

Journal: ESMO open

Published: January 17, 2025

Recent Advances in Immune Checkpoint Inhibitors for Triple-Negative Breast Cancer.

Recent Advances in Immune Checkpoint Inhibitors for Triple-Negative Breast Cancer.

Journal: ImmunoTargets and therapy

Published: January 08, 2025

Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive/HER2-negative BC patients: results from the multicenter PALMARES-2 study.

Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive/HER2-negative BC patients: results from the multicenter PALMARES-2 study.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: October 02, 2024

Showing 1-12 of 85

Last Updated: 09/26/2026